[go: up one dir, main page]

PT3290046T - Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase - Google Patents

Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase

Info

Publication number
PT3290046T
PT3290046T PT17177676T PT17177676T PT3290046T PT 3290046 T PT3290046 T PT 3290046T PT 17177676 T PT17177676 T PT 17177676T PT 17177676 T PT17177676 T PT 17177676T PT 3290046 T PT3290046 T PT 3290046T
Authority
PT
Portugal
Prior art keywords
deficency
prevention
treatment
methods
disorders associated
Prior art date
Application number
PT17177676T
Other languages
English (en)
Inventor
Gallagher Cynthia
Ruddy Stephen
Cornell Manning Mark
Original Assignee
Shire Viropharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51538486&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT3290046(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Shire Viropharma Inc filed Critical Shire Viropharma Inc
Publication of PT3290046T publication Critical patent/PT3290046T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/57—Protease inhibitors from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/16—Blood plasma; Blood serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
PT17177676T 2013-03-15 2014-03-17 Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase PT3290046T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361791399P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PT3290046T true PT3290046T (pt) 2019-02-18

Family

ID=51538486

Family Applications (2)

Application Number Title Priority Date Filing Date
PT17177676T PT3290046T (pt) 2013-03-15 2014-03-17 Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase
PT147623433T PT2968434T (pt) 2013-03-15 2014-03-17 Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase

Family Applications After (1)

Application Number Title Priority Date Filing Date
PT147623433T PT2968434T (pt) 2013-03-15 2014-03-17 Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase

Country Status (30)

Country Link
US (9) US9616111B2 (pt)
EP (3) EP2968434B1 (pt)
JP (9) JP6184581B2 (pt)
KR (4) KR20210021146A (pt)
CN (2) CN111529708A (pt)
AU (3) AU2014232912A1 (pt)
BR (1) BR112015023207A8 (pt)
CA (2) CA2904543C (pt)
CY (2) CY1119419T1 (pt)
DE (1) DE202014011208U1 (pt)
DK (2) DK2968434T3 (pt)
EA (1) EA201591278A1 (pt)
ES (2) ES2639833T3 (pt)
GB (1) GB2530921B (pt)
HK (1) HK1250912B (pt)
HR (2) HRP20171269T1 (pt)
HU (2) HUE036224T2 (pt)
IL (2) IL241549B (pt)
LT (2) LT3290046T (pt)
ME (2) ME02865B (pt)
MX (3) MX389449B (pt)
PL (2) PL3290046T3 (pt)
PT (2) PT3290046T (pt)
RS (2) RS56285B1 (pt)
SG (2) SG11201507616VA (pt)
SI (2) SI3290046T1 (pt)
SM (2) SMT201900141T1 (pt)
TR (1) TR201900319T4 (pt)
WO (1) WO2014145519A2 (pt)
ZA (3) ZA201507604B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3290046T (pt) 2013-03-15 2019-02-18 Shire Viropharma Inc Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase
PT3071219T (pt) * 2013-11-22 2019-02-06 Shire Viropharma Inc Métodos de tratamento da rejeição mediada por anticorpos em pacientes transplantados de órgãos com inibidor da c1-esterase
WO2016131958A1 (en) * 2015-02-20 2016-08-25 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
EP3302540A4 (en) * 2015-05-28 2018-08-22 Cornell University Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
US12209116B2 (en) 2015-11-19 2025-01-28 Takeda Pharmaceutical Company Limited Recombinant human C1 esterase inhibitor and uses thereof
US20190175683A1 (en) * 2016-08-05 2019-06-13 Csl Behring Gmbh Pharmaceutical formulations of c1 esterase inhibitor
EP3504648A1 (en) * 2016-08-23 2019-07-03 CSL Behring GmbH Method of preventing acute attacks of hereditary angioedema associated with c1 esterase inhibitor deficiency
CA3061279A1 (en) * 2017-05-16 2018-11-22 Octapharma Ag C1-esterase inhibitor preparation
WO2019166572A1 (en) 2018-02-28 2019-09-06 Pharming Intellectual Property B.V. Pharmaceutical system for transdermal administration of a c1 -esterase inhibitor
PL3758739T3 (pl) 2018-02-28 2024-09-16 Pharming Intellectual Property B.V. Leczenie i zapobieganie stanowi przedrzucawkowemu
CN112601531A (zh) 2018-06-22 2021-04-02 顺天生化股份有限公司 使用具有复合状态的细胞混合物诱导免疫耐受的抗体、以及所诱导的淋巴细胞、以及使用所诱导的淋巴细胞的细胞治疗剂和治疗法
US12234287B2 (en) 2018-06-22 2025-02-25 Junten Bio Co., Ltd. Method for eliciting infectious immunological tolerance
EP3845652A4 (en) 2018-06-22 2022-04-13 JUNTEN BIO Co., Ltd. ANTIBODIES FOR INDUCING IMMUNTOLERANCE, INDUCED LYMPHOCYTE AND THERAPEUTIC METHOD WITH CELL THERAPY AGENT USING INDUCED LYMPHOCYTE
EP4079325A1 (en) * 2019-12-16 2022-10-26 Nipro Corporation Aggregation inhibitory agent and medical composition and medical device including same
EP3895726A1 (en) 2020-04-17 2021-10-20 Pharming Intellectual Property BV Using c1 esterase inhibitor to treat viral infection-related acute respiratory distress
JP2024525084A (ja) 2021-07-09 2024-07-09 ファーミング・インテレクチュアル・プロパティー・ビー．ブイ． Ｃ１エステラーゼ阻害剤によるウイルス感染関連症状の治療
KR20230046146A (ko) 2021-09-29 2023-04-05 주식회사 엘지에너지솔루션 배터리 제어 시스템 및 방법
WO2025090843A1 (en) * 2023-10-27 2025-05-01 Kansas State University Research Foundation Small-molecule inhibitors of c1s protease and classical complement pathway
CN119823254B (zh) * 2025-03-14 2025-06-03 深圳市卫光生物制品股份有限公司 一种c1酯酶抑制剂重组变体及其制备方法和应用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5304482A (en) 1989-03-06 1994-04-19 The Board Of Regents Of The University Of Texas System Serine protease mutants of the chymotrypsin superfamily resistant to inhibition by their cognate inhibitors
WO1992022320A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. C1 inhibitor variants and treating inflammatory response with c1 inhibitor
US6090777A (en) * 1993-09-01 2000-07-18 Stiching Centraal Laboratorium Van De Bloedtransfusiedienst Van Het Nederlandse Rode Kruis Method to reduce myocardial injury during acute myocardial infarction
WO1997022347A1 (en) 1995-12-18 1997-06-26 Stichting Sanquin Bloedvoorziening Potentiation of complement and coagulation inhibitory properties of c1-inhibitor.
AT409336B (de) * 1999-12-22 2002-07-25 Baxter Ag Verfahren zur herstellung einer c1-esterase-inhibitor (c1-inh)-hältigen zusammensetzung
CA2398707C (en) 2000-01-31 2010-10-26 Pharming Intellectual Property B.V. C1 inhibitor produced in the milk of transgenic mammals
US7067713B2 (en) * 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US6875432B2 (en) 2000-10-12 2005-04-05 Genentech, Inc. Reduced-viscosity concentrated protein formulations
DE10112617A1 (de) 2001-03-14 2002-10-02 Aventis Behring Gmbh Verwendung eines C1-Esterase-Inhibitors zur Verhinderung oder Verzögerung der Abstoßung von Xenotransplantaten in Säugetieren
AU2003300781A1 (en) 2002-09-25 2004-05-04 The Center For Blood Research, Inc. Methods for treating and preventing sepsis using modified c1 inhibitor or fragments thereof
WO2004110356A2 (en) 2003-05-15 2004-12-23 Cbr Institute For Biomedical Research, Inc. Methods for modulating cell-to-cell adhesion using an agonist of c1inh-type protein activity
WO2004100982A1 (en) 2003-05-16 2004-11-25 Pharming Intellectual Property B.V. C1 inhibitor with short half-life for transient treatment
US20060233776A1 (en) 2003-08-19 2006-10-19 Norbert Heimburger C1-inh as a drug for treating viruses pathogenic to humans
US8501705B2 (en) 2003-09-11 2013-08-06 The Board Of Regents Of The University Of Texas System Methods and materials for treating autoimmune and/or complement mediated diseases and conditions
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US7897561B2 (en) 2005-06-06 2011-03-01 Girish J. Kotwal Methods for treatment or prophylaxis of atherosclerosis and reperfusion injury
CA2626356C (en) 2005-10-21 2017-08-22 Catalyst Biosciences, Inc. Modified proteases that inhibit complement activation
ES2369522T3 (es) * 2005-12-21 2011-12-01 Pharming Intellectual Property B.V. Uso de un inhibidor c1 para la prevención de lesiones por isquemia-reperfusión.
EP2380587B1 (en) 2005-12-21 2017-10-25 Pharming Intellectual Property B.V. Use of C1 inhibitor for the prevention of ischemia-reperfusion injury
US7837992B2 (en) 2006-06-22 2010-11-23 Beth Israel Deaconess Medical Center C-1 inhibitor prevents non-specific plasminogen activation by a prourokinase mutant without impeding fibrin-specific fibrinolysis
EP2109457B1 (en) 2007-02-12 2016-01-06 CSL Behring GmbH Therapeutic application of kazal-type serine protease inhibitors
CN104645329A (zh) 2007-11-30 2015-05-27 Abbvie公司 蛋白制剂及其制备方法
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
US20100143325A1 (en) 2008-12-09 2010-06-10 Vascular Laboratory, Inc. Composition And Methods Involving Thrombolytic Agents
EP2453906A4 (en) 2009-07-02 2014-01-15 Musc Found For Res Dev METHOD FOR STIMULATING THE LIVER REGENERATION
CA2777845C (en) 2009-10-16 2017-08-01 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
EP2542569B1 (en) 2010-03-05 2020-09-16 Omeros Corporation Chimeric inhibitor molecules of complement activation
WO2011116291A1 (en) * 2010-03-18 2011-09-22 Thrombolytic Science International Production of human c1 inhibitor in human cells
WO2013013017A2 (en) * 2011-07-21 2013-01-24 Alnylam Pharmaceuticals, Inc. Compositions and methods for modifying the glycosylation of lysosomal storage disorder therapeutics
KR101956585B1 (ko) 2011-09-24 2019-03-11 체에스엘 베링 게엠베하 면역글로불린과 ｃ1-억제제를 사용하는 병용 치료요법
ES2587863T3 (es) * 2011-12-22 2016-10-27 Csl Behring Gmbh Uso de un inhibidor de C1 para el tratamiento de un edema secundario del sistema nervioso central
JP2015512370A (ja) 2012-03-16 2015-04-27 ベルローズ ファーマ，インコーポレーテッド Ｃ１−阻害剤のポリマーコンジュゲート
AU2014243704A1 (en) 2013-03-13 2015-09-10 Creatics Llc Methods and compositions for detecting pancreatic cancer
PT3290046T (pt) 2013-03-15 2019-02-18 Shire Viropharma Inc Composições de c1-inh e para uso na prevenção e no tratamento de distúrbios associados a deficiência de inibidor da c1-esterase
JP6889626B2 (ja) * 2017-06-29 2021-06-18 トキコシステムソリューションズ株式会社 燃料供給システム
JP6935245B2 (ja) * 2017-06-29 2021-09-15 大和ハウス工業株式会社 収容ラック

Also Published As

Publication number Publication date
US20190160157A1 (en) 2019-05-30
JP2021088599A (ja) 2021-06-10
JP2019073545A (ja) 2019-05-16
DE202014011208U1 (de) 2018-08-23
US20180110844A1 (en) 2018-04-26
JP2017105847A (ja) 2017-06-15
EP3290046B1 (en) 2019-01-02
DK3290046T3 (en) 2019-03-18
SMT201900141T1 (it) 2019-05-10
EP2968434A4 (en) 2016-03-02
EP3508213A1 (en) 2019-07-10
AU2020203183A1 (en) 2020-06-04
NZ751555A (en) 2021-07-30
HK1220403A1 (en) 2017-05-05
CA3054718A1 (en) 2014-09-18
DK2968434T3 (en) 2017-09-11
JP6877471B2 (ja) 2021-05-26
JP2018119000A (ja) 2018-08-02
WO2014145519A3 (en) 2014-12-31
ZA201706929B (en) 2019-05-29
RS56285B1 (sr) 2017-12-29
US10201595B2 (en) 2019-02-12
US20180110843A1 (en) 2018-04-26
ES2713004T3 (es) 2019-05-17
LT2968434T (lt) 2017-09-25
IL241549B (en) 2020-08-31
HRP20190270T1 (hr) 2019-04-05
JP6877472B2 (ja) 2021-05-26
JP6877470B2 (ja) 2021-05-26
JP2016516073A (ja) 2016-06-02
JP6422520B2 (ja) 2018-11-14
KR20210129267A (ko) 2021-10-27
CA2904543A1 (en) 2014-09-18
US20160015795A1 (en) 2016-01-21
US20190160158A1 (en) 2019-05-30
ES2639833T3 (es) 2017-10-30
KR102430453B1 (ko) 2022-08-05
US10105423B2 (en) 2018-10-23
WO2014145519A2 (en) 2014-09-18
JP2018119001A (ja) 2018-08-02
EP3290046A1 (en) 2018-03-07
US20180085441A1 (en) 2018-03-29
ME03326B (me) 2019-10-20
EP2968434B1 (en) 2017-06-28
MX373965B (es) 2020-07-13
KR20150135242A (ko) 2015-12-02
BR112015023207A2 (pt) 2017-11-21
RS58351B1 (sr) 2019-03-29
BR112015023207A8 (pt) 2018-01-23
CY1121653T1 (el) 2020-07-31
PL3290046T3 (pl) 2019-05-31
PT2968434T (pt) 2017-09-18
US20180153972A1 (en) 2018-06-07
CY1119419T1 (el) 2018-03-07
CN111529708A (zh) 2020-08-14
JP6184581B2 (ja) 2017-08-23
CA2904543C (en) 2019-10-08
MX389449B (es) 2025-03-20
GB2530921B (en) 2017-09-20
AU2014232912A1 (en) 2015-09-03
AU2018229558B2 (en) 2020-03-05
JP2018119002A (ja) 2018-08-02
JP6473536B2 (ja) 2019-02-20
AU2020203183B2 (en) 2022-06-02
PL2968434T3 (pl) 2018-01-31
LT3290046T (lt) 2019-03-12
JP2019073544A (ja) 2019-05-16
MX2021011946A (es) 2021-11-17
EA201591278A1 (ru) 2016-03-31
US20170224788A1 (en) 2017-08-10
SI3290046T1 (sl) 2019-04-30
AU2018229558A1 (en) 2018-10-04
KR102579789B1 (ko) 2023-09-15
IL276153B (en) 2022-06-01
KR20210021146A (ko) 2021-02-24
NZ710730A (en) 2021-07-30
US10130690B2 (en) 2018-11-20
JP6473535B2 (ja) 2019-02-20
US20200261556A1 (en) 2020-08-20
ME02865B (me) 2018-04-20
HUE036224T2 (hu) 2018-06-28
GB2530921A (en) 2016-04-06
US9616111B2 (en) 2017-04-11
US11364288B2 (en) 2022-06-21
US10080788B2 (en) 2018-09-25
MX2015011281A (es) 2016-03-03
US11534482B2 (en) 2022-12-27
MX2020004724A (es) 2022-01-18
SMT201700415T1 (it) 2017-11-15
TR201900319T4 (tr) 2019-02-21
JP2019073546A (ja) 2019-05-16
KR20220070049A (ko) 2022-05-27
CN105517559A (zh) 2016-04-20
ZA201806793B (en) 2020-01-29
IL276153A (en) 2020-09-30
SI2968434T1 (sl) 2017-11-30
HRP20171269T1 (hr) 2017-11-03
SG10201707598QA (en) 2017-10-30
EP2968434A2 (en) 2016-01-20
SG11201507616VA (en) 2015-10-29
JP6473534B2 (ja) 2019-02-20
GB201519921D0 (en) 2015-12-23
HK1250912B (en) 2020-01-10
ZA201507604B (en) 2018-05-30
HUE041837T2 (hu) 2019-05-28

Similar Documents

Publication Publication Date Title
HRP20190270T1 (hr) C1-inh pripravci i postupci za prevenciju i liječenje poremećaja povezanih s nedostatkom inhibitora c1 esteraze
EP2968318A4 (en) ANTI-PCSK9 COMPOUNDS AND METHODS FOR TREATING AND / OR PREVENTING CARDIOVASCULAR DISEASES
EP3182989A4 (en) Methods and compositions for the prevention and treatment of disease
SG11201702554QA (en) Compositions and methods for the treatment of multiple sclerosis
IL244621A (en) Preparations for the treatment of hypertension and / or fibrosis
IL244622A0 (en) Preparations for the treatment of hypertension and/or fibrosis
PL2968478T3 (pl) Kompozycje i sposoby do leczenia karboksyhemoglobinemii
ZA201408062B (en) Compositions and methods for the treatment of multiple sclerosis
ZA201900984B (en) Methods and compositions for the treatment of warts
EP2994147A4 (en) Compositions and methods for the treatment of tinnitus
EP2934501A4 (en) USES AND METHOD FOR THE TREATMENT OF LIVER DISEASES OR DRESSES
IL245549A0 (en) Compositions and methods for preventing and/or treating disorders associated with dennd1a variant 2
EP3068431A4 (en) Methods and compositions for the treatment of hcmv
EP3225237A4 (en) Fatty acid amides for the prevention and/or treatment of steatohepatitis
EP3104940A4 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
AU2013904048A0 (en) Compositions and methods for the prevention and/or treatment of neurogenic inflammation and/or infla
PL3273997T3 (pl) Kompozycja do leczenia nieżytu nosa
SG11201704282UA (en) Compositions and methods for the treatment of multiple sclerosis
HK1231001A1 (en) Compositions and methods for the prevention and/or treatment of schistosomiasis
AU2013901658A0 (en) Compositions and methods for the treatment of tinnitus
AU2013903571A0 (en) Compositions for the treatment of hypertension and/or fibrosis
AU2013903573A0 (en) Compositions for the treatment of hypertension and/or fibrosis